Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 119

1.

Dynamic gadobutrol-enhanced MRI predicts early response to antivascular but not to antiproliferation therapy in a mouse xenograft model.

Dassler K, Scholle FD, Schütz G.

Magn Reson Med. 2014 May;71(5):1826-33. doi: 10.1002/mrm.24815. Epub 2013 Jun 10.

PMID:
23754607
2.

Evaluation of a novel macromolecular cascade-polymer contrast medium for dynamic contrast-enhanced MRI monitoring of antiangiogenic bevacizumab therapy in a human melanoma model.

Cyran CC, Fu Y, Rogut V, Chaopathomkul B, Wendland MF, Shames DM, Brasch RC.

Acad Radiol. 2013 Oct;20(10):1256-63. doi: 10.1016/j.acra.2013.07.010.

3.

Water exchange-minimizing DCE-MRI protocol to detect changes in tumor vascular parameters: effect of bevacizumab/paclitaxel combination therapy.

Zhu W, Kato Y, Artemov D.

MAGMA. 2014 Apr;27(2):161-70. doi: 10.1007/s10334-013-0389-0. Epub 2013 Jun 27.

4.

Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging.

Zwick S, Strecker R, Kiselev V, Gall P, Huppert J, Palmowski M, Lederle W, Woenne EC, Hengerer A, Taupitz M, Semmler W, Kiessling F.

J Magn Reson Imaging. 2009 May;29(5):1125-33. doi: 10.1002/jmri.21710.

PMID:
19388117
5.

Comparison of gadoteric acid and gadobutrol for detection as well as morphologic and dynamic characterization of lesions on breast dynamic contrast-enhanced magnetic resonance imaging.

Renz DM, Durmus T, Böttcher J, Taupitz M, Diekmann F, Huppertz A, Pfeil A, Maurer MH, Streitparth F, Bick U, Hamm B, Fallenberg EM.

Invest Radiol. 2014 Jul;49(7):474-84. doi: 10.1097/RLI.0000000000000039.

PMID:
24637587
6.

Early antiangiogenic activity of SU11248 evaluated in vivo by dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma.

Marzola P, Degrassi A, Calderan L, Farace P, Nicolato E, Crescimanno C, Sandri M, Giusti A, Pesenti E, Terron A, Sbarbati A, Osculati F.

Clin Cancer Res. 2005 Aug 15;11(16):5827-32.

7.

Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study.

Cyran CC, Paprottka PM, Schwarz B, Sourbron S, Ingrisch M, von Einem J, Pietsch H, Dietrich O, Hinkel R, Bruns CJ, Reiser MF, Wintersperger BJ, Nikolaou K.

AJR Am J Roentgenol. 2012 Feb;198(2):384-91. doi: 10.2214/AJR.11.6951.

PMID:
22268182
8.

Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy.

Akisik MF, Sandrasegaran K, Bu G, Lin C, Hutchins GD, Chiorean EG.

Radiology. 2010 Aug;256(2):441-9. doi: 10.1148/radiol.10091733. Epub 2010 Jun 1.

PMID:
20515976
9.

Dynamic contrast-enhanced MRI for monitoring antiangiogenic treatment: determination of accurate and reliable perfusion parameters in a longitudinal study of a mouse xenograft model.

Song Y, Cho G, Suh JY, Lee CK, Kim YR, Kim YJ, Kim JK.

Korean J Radiol. 2013 Jul-Aug;14(4):589-96. doi: 10.3348/kjr.2013.14.4.589. Epub 2013 Jul 17.

10.

Antivascular ultrasound therapy: magnetic resonance imaging validation and activation of the immune response in murine melanoma.

Hunt SJ, Gade T, Soulen MC, Pickup S, Sehgal CM.

J Ultrasound Med. 2015 Feb;34(2):275-87. doi: 10.7863/ultra.34.2.275.

11.

Early detection of antiangiogenic treatment responses in a mouse xenograft tumor model using quantitative perfusion MRI.

Rajendran R, Huang W, Tang AM, Liang JM, Choo S, Reese T, Hentze H, van Boxtel S, Cliffe A, Rogers K, Henry B, Chuang KH.

Cancer Med. 2014 Feb;3(1):47-60. doi: 10.1002/cam4.177. Epub 2014 Jan 6.

13.

MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer.

Preda A, Novikov V, Möglich M, Turetschek K, Shames DM, Brasch RC, Cavagna FM, Roberts TP.

J Magn Reson Imaging. 2004 Nov;20(5):865-73.

PMID:
15503324
14.

Noninvasive monitoring of therapy-induced microvascular changes in a pancreatic cancer model using dynamic contrast-enhanced magnetic resonance imaging with P846, a new low-diffusible gadolinium-based contrast agent.

Casneuf VF, Delrue L, Van Damme N, Demetter P, Robert P, Corot C, Duyck P, Ceelen W, Boterberg T, Peeters M.

Radiat Res. 2011 Jan;175(1):10-20. doi: 10.1667/RR2068.1. Epub 2010 Oct 7.

PMID:
21175342
15.

Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity.

Messiou C, Orton M, Ang JE, Collins DJ, Morgan VA, Mears D, Castellano I, Papadatos-Pastos D, Brunetto A, Tunariu N, Mann H, Tessier J, Young H, Ghiorghiu D, Marley S, Kaye SB, deBono JS, Leach MO, deSouza NM.

Radiology. 2012 Nov;265(2):426-36. doi: 10.1148/radiol.12112565. Epub 2012 Aug 13.

PMID:
22891356
16.

Quantitative contrast-enhanced ultrasound for imaging antiangiogenic treatment response in experimental osteolytic breast cancer bone metastases.

Merz M, Komljenovic D, Semmler W, Bäuerle T.

Invest Radiol. 2012 Jul;47(7):422-9. doi: 10.1097/RLI.0b013e31824f635a.

PMID:
22659593
17.

Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.

Moestue SA, Huuse EM, Lindholm EM, Bofin A, Engebraaten O, Mælandsmo GM, Akslen LA, Gribbestad IS.

J Magn Reson Imaging. 2013 Nov;38(5):1043-53. doi: 10.1002/jmri.24079. Epub 2013 Mar 21.

PMID:
23908122
18.

Dynamic contrast-enhanced micro-computed tomography correlates with 3-dimensional fluorescence ultramicroscopy in antiangiogenic therapy of breast cancer xenografts.

Pöschinger T, Renner A, Eisa F, Dobosz M, Strobel S, Weber TG, Brauweiler R, Kalender WA, Scheuer W.

Invest Radiol. 2014 Jul;49(7):445-56. doi: 10.1097/RLI.0000000000000038.

PMID:
24598441
19.

Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T.

Muruganandham M, Lupu M, Dyke JP, Matei C, Linn M, Packman K, Kolinsky K, Higgins B, Koutcher JA.

Mol Cancer Ther. 2006 Aug;5(8):1950-7.

20.

PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.

Rudin M, McSheehy PM, Allegrini PR, Rausch M, Baumann D, Becquet M, Brecht K, Brueggen J, Ferretti S, Schaeffer F, Schnell C, Wood J.

NMR Biomed. 2005 Aug;18(5):308-21.

PMID:
15918178
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk